Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Shares Outstanding (2017 - 2025)

Ascendis Pharma A (ASND) has disclosed Shares Outstanding for 9 consecutive years, with $72.1 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 11.24% to $72.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $72.1 million through Dec 2025, up 11.24% year-over-year, with the annual reading at $72.1 million for FY2025, 11.24% up from the prior year.
  • Shares Outstanding hit $72.1 million in Q4 2025 for Ascendis Pharma A, up from $64.9 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $72.1 million in Q4 2025 to a low of $58.3 million in Q4 2022.
  • Historically, Shares Outstanding has averaged $64.5 million across 5 years, with a median of $64.9 million in 2024.
  • Biggest five-year swings in Shares Outstanding: dropped 10.48% in 2022 and later increased 11.24% in 2025.
  • Year by year, Shares Outstanding stood at $65.1 million in 2021, then fell by 10.48% to $58.3 million in 2022, then increased by 6.48% to $62.1 million in 2023, then rose by 4.45% to $64.9 million in 2024, then rose by 11.24% to $72.1 million in 2025.
  • Business Quant data shows Shares Outstanding for ASND at $72.1 million in Q4 2025, $64.9 million in Q4 2024, and $62.1 million in Q4 2023.